🔴 Lantern Pharma is trading 8.26% down in pre-market — no specific catalyst identified

Lantern Pharma is trading 8.26% down at $2.00, versus the August 25, 2026 close of $2.18; no specific catalyst was identified.

• No new company-specific announcement, earnings release, regulatory action, or transaction explaining the August 26 pre-market decline was identified.
• The latest notable company update remains the August 14 second-quarter report on clinical progress and a separate Open-Medicine AI entity; it does not directly explain the move.
• Broader markets are slightly weaker; volume and activity were unavailable, and confidence is low.